|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.25/-0.70
|
企業價值
132.72M
|
資產負債 |
每股賬面淨值
0.75
|
現金流量 |
現金流量率
--
|
損益表 |
收益
1.00M
|
每股收益
0.11
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/01 04:55 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). |